21,081
Participants
Start Date
March 31, 2000
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
PCR/PCR/LDR Strategy
Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
Memorial Sloan Kettering Cancer Center, New York
Columbia University
OTHER
Weill Medical College of Cornell University
OTHER
Icahn School of Medicine at Mount Sinai
OTHER
Memorial Sloan Kettering Cancer Center
OTHER